GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Meta] the dual agonist rule is doing its job and people should stop complaining — 24 comments in the full submission. View in context.
539
c/survodutide·submitted 3 months ago by u/nora_ramos

[Meta] the dual agonist rule is doing its job and people should stop complaining

Cautionbranch of 6 comments

Been lurking in c/dosinglogs for about 15 months and finally have something worth posting. Short version: week 62, 1.7mg, and glucagon is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 39 threads, and the answers split roughly down the middle. What I actually want to know…

Read the full submission and all 24 comments →

This branch

6 comments, started 3 months ago
u/georgi_adebayo13 points·3 months ago·edited

Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.

replysharereportpermalink
u/injection_site_iris0 points·3 months ago

phase 23 data is interesting, phase 14 will be different

replysharereportpermalink
u/slow_logbook_notes301 point·3 months ago

the MASH indication changes the risk calculus

replysharereportpermalink
u/nora_ramos0 points·3 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/hub_opssite staff0 points·3 months ago

Small correction: the trial was 5 weeks, not 37. Does not change your point but people will quote it.

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →